Yahoo Finance

Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS

SAN DIEGO, May 28, 2025 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company focused on developing novel, orally administered therapies for the treatment of neurodegenerative and ...
Mena FN

Transposon To Present Results From Phase 2 Study Of TPN-101 For The Treatment Of C9orf72-Related ALS/FTD At The 2024 Annual NEALS Meeting

(MENAFN- PR Newswire) TPN-101 had lowering effects on key biomarkers of neurodegeneration and neuroinflammation, including neurofilament light chain (NfL) and interleukin 6 (IL-6) Treatment with ...
Yahoo Finance

Transposon to Present Results from Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS/FTD at the 2024 Annual NEALS Meeting

The poster will also be on view during Poster Session 2 on Wednesday, October 23, 2024, from 4:00 to 6:00 pm EDT.
Medindia

Transposon to Present Results from Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS/FTD at the 7th Annual ALS ONE Research Symposium

Treatment with TPN-101 showed clinical benefits on key clinical outcome measures, including the Revised ALS Functional Rating Scale (ALSFRS-R) and Slow Vital Capacity (SVC) SAN DIEGO, Nov. 6, 2024 ...